We are updating our Privacy Policy and Terms and Conditions to help you clearly understand how your personal information is collected, stored and managed. Learn More
Menu Back toNovel-Approaches-to-Clinical-Trials-Safety-and-Valuer-Startification-of-Data

DIA 2018 Global Annual Meeting

The DIA 2018 Global Annual Meeting brings together thousands of innovators from around the globe.


Novel Approaches to Pharmacovigilance Collaboration

    Session Chair(s)
      Jose  Vega, MD

      Jose Vega, MD

      • Vice President, Chief Safety Officer
      • Merck & Co., Inc., United States
    Following the success of its clinical initiatives, TransCelerate launched its first pharmacovigilance projects in 2017, which are now actively engaging with health authorities and delivering both near-term and long-term value. This session will feature a panel of leaders from TransCelerate’s pharmacovigilance teams, as they discuss the future of pharmacovigilance (challenges associated with globalization, data automation, new PV requirements, etc.) and discuss initiatives that TransCelerate has undertaken to address these challenges.
    Learning Objective : • Understand expert perspectives on the future of the field of clinical safety and pharmacovigilance, with a focus on trends, challenges, and how collaborations can work to advance the industry in this space • Discuss what TransCelerate has been doing to address pharmacovigilance challenges, and what it plans to deliver in the long-term
    Speaker(s)
      Jose  Vega, MD

      Industry Collaboration to Improve Patient Safety: TransCelerate’s Long-Term Vision to Address Pharmacovigilance Challenges

      Jose Vega, MD

      • Vice President, Chief Safety Officer
      • Merck & Co., Inc., United States
      Peter  Verdru, MD

      Evaluating the Value of Safety Information Data Sources: Gathering Evidence to Illustrate a Hierarchy of Value

      Peter Verdru, MD

      • Vice President, Head of Patient Safety
      • UCB Biopharma S.P.R.L., Belgium
      Ajay B. Singh, MD

      Interpretation of PV Regulations

      Ajay B. Singh, MD

      • Team Leader, Safety Evaluation and Risk Management
      • GlaxoSmithKline, United States
      Jeremy  Jokinen, PhD, MS

      Value of Safety Information Data Sources

      Jeremy Jokinen, PhD, MS

      • Senior Director, Decision Sciences
      • AbbVie, Inc., United States
      Gerald J. Dal Pan

      FDA Perspective

      Gerald J. Dal Pan

      • Director, Office of Pharmacovigilance and Epidemiology, OSE,CDER
      • FDA, United States